EUVIMEDEUVIMED entdecken
Crossref

Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy

Jiangkun Yu, Xue Lin, Wenshan Huang, Shisong Han iD, Jie Qin, Jie-Hua Xu

Molecular Pharmaceutics · 02.02.2026 · 23 (2) · 893-904

DOI: 10.1021/acs.molpharmaceut.5c01251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 23.01.2026. Verfasst von Jiangkun Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Aptamers, Nucleotide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Zhuhai People?s Hospital, Zhuhai Science and Technology Innovation Bureau, Guangdong Medical Science and Technology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) demands advanced multimodal therapies to overcome heterogeneity-driven treatment resistance. Although aptamers exhibit superior targeting advantages over antibodies, their clinical translation remains severely hindered by ambiguous target identification and the limited drug-loading capacity of direct aptamer-drug conjugates. To address this, we first identified vascular endothelial growth factor receptor 2 (VEGFR2) as the target of the HCC-specific aptamer JHIT2e using an integrated approach combining 3D photo-cross-linking chip technology, surface plasmon resonance (SPR), and liquid chromatography-mass spectrometry (LC-MS). Building on this, we engineered a multifunctional DNA nanotrain (131I-NTs-Dox, namely, 131I-labeled DNA nanotrains loaded with doxorubicin) comprising three key components: the JHIT2e aptamer as a navigation module for tumor-specific targeting, hybridization chain reaction (HCR)-assembled dsDNA duplexes as "carriages" intercalated with doxorubicin (Dox), and carboxyfluorescein (FAM)-terminated termini radiolabeled with iodine-131 (131I) via an optimized chloramine T method. Notably, this FAM-mediated labeling strategy significantly enhanced radiolabeling efficiency to 93%, surpassing conventional tyrosine-based methods (70-85%). Each nanotrain entity achieved an unprecedented payload capacity of 50 Dox molecules and 80 131I atoms. In vitro studies demonstrated that 131I-NTs-Dox exhibits specific affinity for HepG2 cells, rapid lysosomal endocytosis, and enhanced tumor accumulation. Furthermore, the platform synergistically inhibited HCC cell viability through dual chemoradiotherapeutic mechanisms: Dox-induced DNA repair inhibition and 131I-mediated DNA damage. Collectively, 131I-NTs-Dox represents a scalable nanoplatform with high-precision HCC targeting, dual-modal therapeutic efficacy, and promising clinical potential for chemoradiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAptamers, NucleotideHumansDoxorubicinAnimalsVascular Endothelial Growth Factor Receptor-2ChemoradiotherapyMiceCell Line, TumorIodine RadioisotopesDNA NanostructuresHep G2 CellsMice, Nude

Stichwörter der Autor:innen

aptamer target identificationaptamer-conjugated DNA nanotrainchemoradiotherapyhepatocellular carcinomavascular endothelial growth factor receptor 2

Substanzen

Aptamers, NucleotideDoxorubicinVascular Endothelial Growth Factor Receptor-2Iodine RadioisotopesKDR protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, Guangdong 519099, China.
  • Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China.

ORCID-Profile: Shisong Han

Förderung

  • Zhuhai People?s Hospital
  • Zhuhai Science and Technology Innovation Bureau
  • Guangdong Medical Science and Technology Research Foundation

Zitieren

APA

Yu, J., Lin, X., Huang, W., Han, S., Qin, J., & Xu, J. H. (2026). Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy. Molecular Pharmaceutics, 23(2), 893-904. https://doi.org/10.1021/acs.molpharmaceut.5c01251

Vancouver

Yu J, Lin X, Huang W, Han S, Qin J, Xu JH. Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy. Molecular Pharmaceutics. 2026;23(2):893-904. doi:10.1021/acs.molpharmaceut.5c01251

BibTeX
@article{Yu2026,
  author = {Yu, Jiangkun and Lin, Xue and Huang, Wenshan and Han, Shisong and Qin, Jie and Xu, Jie-Hua},
  title = {Target Identification of the Hepatocellular Carcinoma-Specific Aptamer JHIT2e and Construction of Engineered Nanotrains for Synergistic Chemoradiotherapy},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {2},
  pages = {893--904},
  doi = {10.1021/acs.molpharmaceut.5c01251}
}
Kostenlos starten →